Evidence map›Paper›PMID 31733125›Full record

ArticleBritish journal of haematology2020

Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP.

Young-Woo Jeon, Joo-Hyun O, Kyung-Sin Park, Gi June Min, Sung-Soo Park, Jae-Ho Yoon, Ki-Seong Eom, Chang-Ki Min, Seok-Goo Cho

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. The Prognostic Utility ofFrontiers in oncology · 2022
    Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Young-Woo JeonDivision of Lymphoma-Myeloma of Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0003-3362-8200
Joo-Hyun OCatholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kyung-Sin ParkCatholic University Lymphoma Group, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Gi June MinDivision of Lymphoma-Myeloma of Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Sung-Soo ParkDivision of Lymphoma-Myeloma of Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0002-8826-4136
Jae-Ho YoonDivision of Lymphoma-Myeloma of Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0002-2145-9131
Ki-Seong EomDivision of Lymphoma-Myeloma of Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Chang-Ki MinDivision of Lymphoma-Myeloma of Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Seok-Goo ChoDivision of Lymphoma-Myeloma of Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0002-5429-4839
The Catholic University of Korea Seoul St. Mary's Hospital · KRThe Catholic University of Korea Yeouido St. Mary's Hospital · KR

Funding

Korea Healthcare Technology R&D ProjectMinistry for Health, Welfare, and Family Affairs, Republic of KoreaMinistry of Education, Science, and TechnologyNational Research Foundation of Korea
6 · The paper itself

Abstract

Although

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFemaleHumansLymphoma, Mantle-CellMaleMiddle AgedPositron-Emission TomographyPrednisonePrognosisProgression-Free SurvivalRituximabCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineinterim 18F-FDG PETmantle cell lymphomaprognosisR-CHOPtreatment response

Identifiers

PMID31733125
PMCPMC7155042
OpenAlexW2983647587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.